RENIER JOSEPH BRENTJENS

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor
    John Maher
    Department of Human Genetics Medicine, Gene Transfer and Somatic Cell Engineering Laboratory, and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Biotechnol 20:70-5. 2002
  2. pmc CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Sci Transl Med 5:177ra38. 2013
  3. doi request reprint Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen
    Renier J Brentjens
    Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA
    Hematology Am Soc Hematol Educ Program 2012:143-51. 2012
  4. doi request reprint Novel approaches to the immunotherapy of B-cell malignancies: An update
    Renier J Brentjens
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Hematol Malig Rep 1:258-63. 2006
  5. ncbi request reprint Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:5426-35. 2007
  6. ncbi request reprint Novel approaches to immunotherapy for B-cell malignancies
    Renier J Brentjens
    Hematology Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Hematol Rep 4:64-72. 2005
  7. ncbi request reprint Novel approaches to immunotherapy for B-cell malignancies
    Renier J Brentjens
    Hematology Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 6:339-47. 2004
  8. ncbi request reprint Cellular therapies in acute lymphoblastic leukemia
    Renier J Brentjens
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY 10065, USA
    Curr Opin Mol Ther 11:375-82. 2009
  9. pmc Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 118:4817-28. 2011
  10. ncbi request reprint Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Med 9:279-86. 2003

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor
    John Maher
    Department of Human Genetics Medicine, Gene Transfer and Somatic Cell Engineering Laboratory, and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Biotechnol 20:70-5. 2002
    ..These findings have important implications for adoptive immunotherapy of cancer, especially in the context of tumor cells that fail to express major histocompatibility complex antigens and co-stimulatory molecules...
  2. pmc CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Sci Transl Med 5:177ra38. 2013
    ....
  3. doi request reprint Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen
    Renier J Brentjens
    Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA
    Hematology Am Soc Hematol Educ Program 2012:143-51. 2012
    ..Recent preclinical studies support additional genetic modifications of CAR-modified T cells to achieve optimal clinical efficacy using this novel adoptive cellular therapy...
  4. doi request reprint Novel approaches to the immunotherapy of B-cell malignancies: An update
    Renier J Brentjens
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Hematol Malig Rep 1:258-63. 2006
    ..Whether findings from these clinical trials, in combination with further preclinical studies, will ultimately translate into improved survival of patients with B-cell malignancies remains to be seen...
  5. ncbi request reprint Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:5426-35. 2007
    ..Here, we investigate the etiologies of treatment failure in this model and design approaches to enhance the efficacy of this adoptive strategy...
  6. ncbi request reprint Novel approaches to immunotherapy for B-cell malignancies
    Renier J Brentjens
    Hematology Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Hematol Rep 4:64-72. 2005
    ..However, whether the promising preclinical and phase I clinical data presented here will ultimately translate into improved survival of patients with B-cell malignancies remains largely unknown...
  7. ncbi request reprint Novel approaches to immunotherapy for B-cell malignancies
    Renier J Brentjens
    Hematology Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 6:339-47. 2004
    ..However, whether the promising preclinical and phase I clinical data presented here will ultimately translate into improved survival of patients with B-cell malignancies remains largely unknown...
  8. ncbi request reprint Cellular therapies in acute lymphoblastic leukemia
    Renier J Brentjens
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY 10065, USA
    Curr Opin Mol Ther 11:375-82. 2009
    ..Whether these novel adoptive cell therapies will ultimately result in improved clinical outcomes remains to be determined...
  9. pmc Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 118:4817-28. 2011
    ..These studies are registered at www.clinicaltrials.org as #NCT00466531 (CLL protocol) and #NCT01044069 (B-ALL protocol)...
  10. ncbi request reprint Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Med 9:279-86. 2003
    ..In addition, transduced T cells from patients with chronic lymphocytic leukemia (CLL) effectively lyse autologous tumor cells. These findings strongly support the clinical feasibility of this therapeutic strategy...
  11. ncbi request reprint T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
    Matthias T Stephan
    Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York 10021, USA
    Nat Med 13:1440-9. 2007
    ..This new strategy of endowing T cells with constitutively expressed costimulatory ligands could be extended to other ligand-receptor pairs and used to enhance any targeted adoptive transfer therapy...
  12. ncbi request reprint Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes
    Isabelle Riviere
    Department of Medicine, Gene Transfer and Somatic Cell Engineering Laboratory, Immunology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Hematol Rep 3:290-7. 2004
    ..T cells can also be engineered in an attempt to control their homing, to increase the safety of adoptive T-cell therapies, and express markers that can be tracked by noninvasive imaging technologies...
  13. pmc Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen
    Alena A Chekmasova
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:3594-606. 2010
    ....
  14. ncbi request reprint Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells
    Jae H Park
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Discov Med 9:277-88. 2010
    ....
  15. pmc Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy
    Daniel Hollyman
    Gene Transfer and Somatic Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunother 32:169-80. 2009
    ..It can also be adapted for other clinical trials involving the expansion and transduction of patient or donor T cells using any CAR or T-cell receptor...
  16. ncbi request reprint Somatic cell engineering and the immunotherapy of leukemias and lymphomas
    Renier J Brentjens
    Department of Medicine and Clinical Laboratories, Leukemia Service Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Adv Pharmacol 51:347-70. 2004
  17. pmc Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo
    Il Kang Na
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY
    Blood 116:e18-25. 2010
    ..Because NFAT plays an important role in a wide range of cell types, our system could provide new insights into a variety of biologic processes...
  18. ncbi request reprint Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application
    Alfonso Quintas-Cardama
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Gene Ther 18:1253-60. 2007
    ....
  19. ncbi request reprint Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer
    Alena A Chekmasova
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Discov Med 9:62-70. 2010
    ..To this end, adoptive T cell immunotherapy strategies for the treatment of ovarian carcinomas appear to be particularly promising and are currently being investigated at several centers in both pre-clinical and clinical settings...
  20. pmc Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
    Johannes L Zakrzewski
    Department Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Biotechnol 26:453-61. 2008
    ..We conclude that ex vivo generated MHC-disparate T-cell precursors from any donor can be used universally for 'off-the-shelf' immunotherapy, and can be further enhanced by genetic engineering for targeted immunotherapy...
  21. pmc Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase
    Elmer B Santos
    Department of Radiology, Memorial Sloan Kettering Cancer Center MSKCC, 1275 York Avenue, New York, New York 10021, USA
    Nat Med 15:338-44. 2009
    ..This sensitive imaging technology has application to many in vivo cell-based studies in a wide array of mouse models...

Research Grants4

  1. Genetic Targeting of T cells to B cell malignancies
    Renier Brentjens; Fiscal Year: 2005
    ..The data derived from these studies will be applied to the rational development of future clinical trials in human subjects with B cell malignancies. ..
  2. Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
    RENIER JOSEPH BRENTJENS; Fiscal Year: 2010
    ..The goal of this project is to improve the function of these cells to make them better suited to treat patients with persistent cancer after chemotherapy. ..
  3. Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
    RENIER JOSEPH BRENTJENS; Fiscal Year: 2010
    ..The goal of this project is to improve the function of these cells to make them better suited to treat patients with persistent cancer after chemotherapy. ..